JP2017523184A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523184A5
JP2017523184A5 JP2017504404A JP2017504404A JP2017523184A5 JP 2017523184 A5 JP2017523184 A5 JP 2017523184A5 JP 2017504404 A JP2017504404 A JP 2017504404A JP 2017504404 A JP2017504404 A JP 2017504404A JP 2017523184 A5 JP2017523184 A5 JP 2017523184A5
Authority
JP
Japan
Prior art keywords
seq
composition
polypeptide
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017504404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523184A (ja
JP6940916B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/042684 external-priority patent/WO2016019034A1/en
Publication of JP2017523184A publication Critical patent/JP2017523184A/ja
Publication of JP2017523184A5 publication Critical patent/JP2017523184A5/ja
Priority to JP2021142801A priority Critical patent/JP2021191781A/ja
Application granted granted Critical
Publication of JP6940916B2 publication Critical patent/JP6940916B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017504404A 2014-07-30 2015-07-29 フラジェリン組成物および使用 Expired - Fee Related JP6940916B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021142801A JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462031116P 2014-07-30 2014-07-30
US62/031,116 2014-07-30
US201562110744P 2015-02-02 2015-02-02
US62/110,744 2015-02-02
US201562117366P 2015-02-17 2015-02-17
US62/117,366 2015-02-17
PCT/US2015/042684 WO2016019034A1 (en) 2014-07-30 2015-07-29 Flagellin compositons and uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021142801A Division JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Publications (3)

Publication Number Publication Date
JP2017523184A JP2017523184A (ja) 2017-08-17
JP2017523184A5 true JP2017523184A5 (enExample) 2021-01-07
JP6940916B2 JP6940916B2 (ja) 2021-09-29

Family

ID=55218277

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017504404A Expired - Fee Related JP6940916B2 (ja) 2014-07-30 2015-07-29 フラジェリン組成物および使用
JP2017504354A Expired - Fee Related JP6646039B2 (ja) 2014-07-30 2015-07-30 フラジェリンベースの薬剤および効果的なワクチン接種を含めた使用
JP2021142801A Pending JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017504354A Expired - Fee Related JP6646039B2 (ja) 2014-07-30 2015-07-30 フラジェリンベースの薬剤および効果的なワクチン接種を含めた使用
JP2021142801A Pending JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Country Status (14)

Country Link
US (9) US10202426B2 (enExample)
EP (2) EP3174893B1 (enExample)
JP (3) JP6940916B2 (enExample)
KR (1) KR20170031251A (enExample)
CN (2) CN107087411B (enExample)
AU (2) AU2015296555B2 (enExample)
BR (1) BR112017001796A2 (enExample)
CA (2) CA2994218A1 (enExample)
EA (2) EA035372B1 (enExample)
ES (1) ES2816630T3 (enExample)
IL (2) IL250334B (enExample)
MX (2) MX385845B (enExample)
WO (2) WO2016019034A1 (enExample)
ZA (1) ZA201701286B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202426B2 (en) * 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
JP6762030B2 (ja) 2014-11-20 2020-09-30 国立研究開発法人医薬基盤・健康・栄養研究所 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
UY37816A (es) 2017-07-20 2019-02-28 Spogen Biotech Inc Polipéptidos bioactivos para mejorar la protección, crecimiento y productividad en plantas
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11660331B2 (en) 2017-11-09 2023-05-30 The Scripps Research Institute Heroin vaccine
JP7037930B2 (ja) * 2017-12-19 2022-03-17 株式会社小糸製作所 車両の運転支援装置、命令表示装置及び車両用灯具。
CN109879940A (zh) * 2017-12-25 2019-06-14 苏州和锐生物科技有限公司 鞭毛g多肽、抗体捕获器件及试剂盒
CN112203675A (zh) * 2018-04-24 2021-01-08 基因组保护股份有限公司 用于改善虚弱和衰老的方法
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
US20220024991A1 (en) * 2018-12-07 2022-01-27 Genome Protection, Inc. Engineered flagellin-derived compositions and uses
CN111718417B (zh) * 2019-03-19 2022-10-14 宁波鲲鹏生物科技有限公司 含有荧光蛋白片段的融合蛋白及其用途
KR102169663B1 (ko) * 2019-03-28 2020-10-26 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
CN110157655B (zh) * 2019-05-22 2021-06-01 中国兽医药品监察所 一种无毒性气肿疽梭菌基因工程亚单位疫苗用菌种及其应用
WO2021041822A1 (en) * 2019-08-30 2021-03-04 Genome Protection. Inc. Methods of increasing vaccine efficacy
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
JP7598660B2 (ja) * 2020-06-04 2024-12-12 ザ カトリック ユニバーシティ オブ コリア インダストリー－アカデミック コーオペレイション ファウンデーション フラジェリン由来のｔｌｒ５アゴニストを有効成分として含む抗がん剤組成物
TWI746188B (zh) * 2020-09-28 2021-11-11 中山醫學大學 篩選治療腦炎藥物之平台及其方法
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
KR20240027752A (ko) * 2021-06-30 2024-03-04 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 플라겔린의 폐 전달을 위한 에어로졸 조성물
KR102483177B1 (ko) * 2021-07-09 2022-12-29 전남대학교산학협력단 탈-면역 플라젤린 및 이를 포함하는 백신 조성물
KR102514849B1 (ko) * 2021-10-28 2023-03-28 전남대학교산학협력단 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물
IL317229A (en) * 2022-06-01 2025-01-01 Flag Bio Inc RNA helpers, methods and uses thereof
WO2024035137A1 (ko) * 2022-08-10 2024-02-15 주식회사 메디스팬 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도
US20240173397A1 (en) * 2022-11-29 2024-05-30 George Mason University Limiting viral infection and replication in stem cells
WO2025172452A1 (en) * 2024-02-14 2025-08-21 Institut National de la Santé et de la Recherche Médicale Combination for treating bacterial infection due to pseudomonas aeruginosa antibiotic-resistant strain
JP1793517S (ja) * 2024-08-22 2025-04-21 船舶用推進機用リモートコントローラー

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3007812A (en) 1957-02-11 1961-11-07 Allied Chem Water-repellent compositions, method of water-proofing porous surfaces therewith, and resulting water-repellent surfaces
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
EP0449958B9 (en) * 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
WO1992005816A1 (de) 1990-09-28 1992-04-16 Gebrüder Sulzer Aktiengesellschaft Hohlnadel zur medizinischen verwendung und verfahren zur herstellung derartiger hohlnadeln
EP0967279B1 (en) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
US5693476A (en) 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
US20020009747A1 (en) 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
WO2001040280A2 (en) 1999-11-29 2001-06-07 Inotek Corporation Composition and method for treating a microbial infection
CN1447819B (zh) 2000-01-31 2011-06-22 妙甯公司 人cyr61
US7300749B2 (en) 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
WO2002044363A1 (en) 2000-11-28 2002-06-06 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
ATE463505T1 (de) 2001-04-20 2010-04-15 Inst Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
CA2462638A1 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7078165B2 (en) 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
US7638485B2 (en) 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
WO2005056054A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
AU2004296828B2 (en) * 2003-12-02 2011-07-07 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
US20050266391A1 (en) 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
WO2006039701A1 (en) 2004-10-01 2006-04-13 University Of South Florida Flagellin-based adjuvants and vaccines
JP5094407B2 (ja) 2004-12-16 2012-12-12 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ Ｙｅｒｓｉｎｉａｐｅｓｔｉｓの免疫療法におけるフラジェリンの使用
EP1838340B1 (en) 2004-12-22 2018-04-04 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
WO2007030581A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
US20070269406A1 (en) 2005-12-14 2007-11-22 Ichim Thomas E Transcatheter tumor immunoembolization
US20090081157A1 (en) 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
EP2114427B1 (en) 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
WO2008157473A1 (en) 2007-06-15 2008-12-24 Immurx, Inc. Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens
CA2695385A1 (en) 2007-07-31 2009-02-05 Atul Bedi Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
KR101811965B1 (ko) 2007-11-07 2017-12-22 셀덱스 쎄라퓨틱스, 인크. 인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체
WO2009102818A1 (en) 2008-02-11 2009-08-20 Cleveland Biolabs, Inc. Method for reducing the effects of chemotheraphy using flagellin related polypeptides
CN102170911B (zh) * 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
US8486408B2 (en) * 2008-10-03 2013-07-16 Emory University Methods for the treatment of graft-versus-host disease
BRPI1010937A2 (pt) 2009-05-21 2019-09-24 Astrazeneca Ab composto, uso de um composto, e, método para tratar câncer
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
CA2777198C (en) * 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
EP2547362B1 (en) * 2010-03-17 2021-08-25 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
US9683020B2 (en) * 2011-08-01 2017-06-20 Emory University VLPS containing ligands and methods related thereto
CN102965386A (zh) * 2011-09-02 2013-03-13 中国人民解放军军事医学科学院放射与辐射医学研究所 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法
CN102772795B (zh) * 2012-08-06 2015-07-29 中国人民解放军疾病预防控制所 布鲁氏菌鞭毛蛋白bmeii1112在制备布鲁氏菌亚单位疫苗中的应用
US10202426B2 (en) * 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses

Similar Documents

Publication Publication Date Title
CL2020001897A1 (es) Tratamientos contra el cáncer de útero. (divisional solicitud 201802508)
EA202191027A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
PE20240645A1 (es) Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
MX2021002543A (es) Proceso para la preparacion de composiciones de vacunas.
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
MX2018002480A (es) Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer.
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2023014457A (es) Peptidos antigenicos para la prevencion y el tratamiento del cancer.
BR112022008750A2 (pt) Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
JP2019500026A5 (enExample)
RU2016107873A (ru) Пептиды
JP2009520758A5 (enExample)
JP2016520620A5 (enExample)
FI3737397T3 (fi) Prameen kohdistetut syöpärokotteet ja niiden käytöt
JP2018509423A5 (enExample)
CA2755897A1 (en) Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
UA124331C2 (uk) Пептид, здатний зв'язуватися з молекулою головного комплексу гістосумісності (mhc) людини i класу
US8575319B2 (en) Cleavable vaccine compositions and uses thereof and methods of making and using the same
WO2022155403A1 (en) Recombinant polypeptides, conjugates comprising the same, and uses thereof
MX343848B (es) Vacuna de her2 dna como tratamiento adjunto para canceres en animales de compañía.
MX2022002293A (es) Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso.
CN103254313B (zh) 组合的ctl抗原表位及其应用
EA202190186A1 (ru) Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака